Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

19

Revenue 2017

Keytruda

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Keytruda was produced by Merck & Co..

MSD withdraws Keytruda’s US indication for small cell lung cancer

MSD withdraws Keytruda’s US indication for small cell lung cancer Keytruda failed to meet this requirement in the KEYNOTE-604 trial, as announced in January 2020. ... Keytruda remains a foundational treatment for certain patients with metastatic non-small cell lung cancer.

Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US

Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US In its new NSCLC setting, Libtayo will take on Merck &Co/MSD’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab). ... Keytruda has become the new standard-of-care treatment for newly-diagnosed advanced NSCLC, after first winning approval in

AZ withdraws Imfinzi in the US for advanced bladder cancer after post-marketing study fail

AZ withdraws Imfinzi in the US for advanced bladder cancer after post-marketing study fail NMIBC). A number of immunotherapies are approved for bladder cancer, including Merck &Co/MSD’s Keytruda (pembrolizumab) which became the first checkpoint inhibitor to be approved in the US for NMIBC

New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer

New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer The overall response rate (ORR) for Keytruda plus Lenvima-treated patients was 71% compared to 36.1% in the Sutent group. ... In this trial, Keytruda plus Lenvima demonstrated superior efficacy benefits compared with Sutent.

BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer

BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer Both Opdivo combinations will compete with Merck &Co/MSD’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab) plus Pfizer’s TKI Inlyta (axitinib), after the combination treatment received FDA approval in the same ... Topline results from the

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...